U.S., Sept. 11 -- ClinicalTrials.gov registry received information related to the study (NCT07166549) titled 'Bispecific CAR T Cells for B-cell Malignancies (BaseCAR-01 Trial)' on Sept. 03.
Brief Summary: This study is to provide locally produced, bispecific CD19 CD20 CAR T cells to patients with B-cell lymphoma/leukemia who have no access to commercial CAR T cells or who have relapsed thereafter. The primary objective is to assess the safety of bispecific anti-CD19, anti- CD20 CAR T cell-therapies after lymphodepleting chemotherapy in patients with B cell malignancies with exhausted standard treatment options.
Study Start Date: Nov., 2025
Study Type: INTERVENTIONAL
Condition:
B Cell Malignancies
B-cell Leukemia
B Cell Lymphoma
Bispeci...